The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
Secretary of Education Betsy DeVos and her family have seen their investments skyrocket since President Donald Trump started enacting pro-business policies. Meanwhile, DeVos...Politicsread more
The deal between the White House and Democrats was earlier expected to raise the debt ceiling for two years and permanently end the sequester.Politicsread more
See which stocks are posting big moves after the bell on July 22.Market Insiderread more
The construction industry is heavily dependent on Hispanic and Latino workers, a workforce that diminished during the last housing crisis and has not come close to full...Real Estateread more
The deal could be announced as soon as next week, according to the report.Technologyread more
Former NFL offensive lineman Jeff Hatch, who had previously been candid about his own struggles with opioid addiction and substance abuse, pleaded guilty Friday to a drug...Politicsread more
A group of gold miners stocks, "BAANG," are better plays than mega-cap FAANG names, according to John Roque, technical analyst at Wolfe Research.Marketsread more
T-Mobile is choosing to move ahead with a merger with Sprint even though it will prop up Dish Network as a new, possibly disruptive fourth U.S. wireless competitor.Technologyread more
Danger is lurking in the stock market: An abrupt sell-off could be around the corner if the Federal Reserve doesn't deliver the rate cut the market expects next week, the firm...Marketsread more
The deal, while not yet approved by each company's board, is expected to be announced before the open of trading tomorrow, barring a last minute setback. An exact price and specific composition of the deal's stock and cash components was not shared by sources.
Allergan's decision to sell to Actavis comes after a long battle to avoid the clutches of Valeant, which teamed with the hedge fund Pershing Square in making an unsolicited bid for Allergan last spring.
Actavis has been acquiring companies at a breakneck pace. The Allergan deal, which will represent it's biggest purchase yet by far, follows closely on the heels of its acquisition of Forest Labs.
Valeant, which has not been contacted by Allergan, is likely to abandon its bid for the company in the face of the Actavis deal, according to people close to that company.
The Actavis deal will include a "typical" break fee, according to people close to the situation, but that fee could still represent as much as a $2 billion ticket that would need to be paid by Valeant, were it to try and outbid Actavis.